TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18401693

Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 0
Study: 15947502

Group type: EXPERIMENTAL
Intervention: Lidocaine gel 2% with intracameral lidocaine 1%
Number of subjects: 39

Group type: COMPARATOR
Intervention: Combined topical anesthesia (bupivacaine 0.5, oxybuprocaine, and diclofenac eyedrops) with intracameral lidocaine 1%
Number of subjects: 39
Study: 12889589

Group type: EXPERIMENTAL
Intervention: Intravenous and oral broad spectrum Ampicillin/Amoxicillin and Erythromycin therapy during conservative management of pPROM before 32 weeks' gestation
Number of subjects: 0
Study: 10489079

Group type: EXPERIMENTAL
Intervention: Reassuring manipulation (experimenter said subject was physiologically calm and relaxed)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Arousing manipulation (experimenter said subject was physiologically aroused and nervous)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition (experimenter remained silent)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Reassuring manipulation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Arousing manipulation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Reassuring manipulation vs Arousing manipulation
Number of subjects: 60
Study: 8997659

Group type: EXPERIMENTAL
Intervention: Small particle size tetracycline in gel
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Large particle size tetracycline in gel
Number of subjects: 31
Study: 1631985

Group type: EXPERIMENTAL
Intervention: Simple CPAP with a 10 l latex balloon reservoir
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CR60 CPAP
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Down's CPAP
Number of subjects: 10

Group type: COMPARATOR
Intervention: High-flow systems (CR60 CPAP and Down's CPAP)
Number of subjects: 10
Study: 6490937

Group type: EXPERIMENTAL
Intervention: Parents as Teachers course
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Parents as Advocates course
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study: 31048579

Group type: EXPERIMENTAL
Intervention: MSI-high group
Number of subjects: 393

Group type: COMPARATOR
Intervention: Microsatellite-stable subgroup
Number of subjects: 393
Study: 29422181

Group type: EXPERIMENTAL
Intervention: Music intervention (four consecutive weekly 1-hour music classes)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no intervention, maintained usual lifestyle habits)
Number of subjects: 48
Study: 26787792

Group type: EXPERIMENTAL
Intervention: Sugammadex (0.25, 0.5, 0.75, 1.0, or 1.25 mg kg(‐1) i.v.)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Neostigmine (10, 25, 40, 55, or 70 µg kg(‐1) i.v.)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Saline (control group, n=9)
Number of subjects: 99
Study: 25488160

Group type: EXPERIMENTAL
Intervention: mini volume loading test (mVLT) in dehydrated subjects
Number of subjects: 12

Group type: COMPARATOR
Intervention: mini volume loading test (mVLT) in hydrated subjects
Number of subjects: 12
Study: 23141722

Group type: EXPERIMENTAL
Intervention: Ultrasonic inserts
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gracey curettes
Number of subjects: 30
Study: 20816042

Group type: EXPERIMENTAL
Intervention: Armodafinil 200 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Armodafinil 50 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Armodafinil 100 mg
Number of subjects: 60
Study: 17432112

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LIP 394
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin or statins
Number of subjects: 0
Study: 16087943

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (12 doses) followed by fluorouracil/doxorubicin/cyclophosphamide (FAC) every 3 weeks
Number of subjects: 258

Group type: COMPARATOR
Intervention: Once every 3 weeks paclitaxel (4 cycles) followed by fluorouracil/doxorubicin/cyclophosphamide (FAC) every 3 weeks
Number of subjects: 258
Study: 12461672

Group type: EXPERIMENTAL
Intervention: Fermentable carbohydrate (FC) intake
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Indirect calorimetry (IDC)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Energy availability and requirement estimates
Number of subjects: 72
Study: 11825402

Group type: EXPERIMENTAL
Intervention: Portacaval shunt with H‐grafts of 8 mm diameter with external ring reinforced (20 patients)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Side‐to‐side portacaval shunt (11 patients)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Proximal splenorenal shunt (17 patients)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: H-graft shunting (20 patients)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: H-graft shunting (19 survivals)
Number of subjects: 48
Study: 8597010

Group type: EXPERIMENTAL
Intervention: Diet manipulation to exclude foods that provoke symptoms
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (documenting but not altering food intake)
Number of subjects: 18
Study: 1812628

Group type: EXPERIMENTAL
Intervention: Coronary balloon angioplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary bypass surgery
Number of subjects: 0
Study: 6119249

Group type: EXPERIMENTAL
Intervention: Prophylactic metronidazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrauterine extra‐amniotic prostaglandin supplemented by curettage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30959546

Group type: EXPERIMENTAL
Intervention: Arthroscopic debridement surgery combined with partial fibula osteotomy (Group B)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Arthroscopic debridement surgery only (Group A)
Number of subjects: 17
Study: 30215763

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole use
Number of subjects: 54113
Study: 26427107

Group type: EXPERIMENTAL
Intervention: Shoushen granule
Number of subjects: 156

Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 156
Study: 24647391

Group type: EXPERIMENTAL
Intervention: Aromatic amino acid (AAA) supplementation (330 mg · kg(‐1) · d(‐1))
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ala (isonitrogenous control)
Number of subjects: 22
Study: 22334767

Group type: EXPERIMENTAL
Intervention: Individualized training program designed to improve activity of daily living (ADL) and physical capacity, lasting for 3 months.
Number of subjects: 98

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 98
Study: 20646753

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 119

Group type: COMPARATOR
Intervention: PQ1
Number of subjects: 119
Study: 17668878

Group type: EXPERIMENTAL
Intervention: Pravastatin (80 mg/day)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study: 16355489

Group type: EXPERIMENTAL
Intervention: Culturally tailored, faith-based weight loss intervention for 12 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Culturally tailored weight loss intervention with no active faith component
Number of subjects: 59
Study: 12196230

Group type: EXPERIMENTAL
Intervention: Endovascular procedure
Number of subjects: 22

Group type: COMPARATOR
Intervention: Neurosurgical procedure
Number of subjects: 22
Study: 10682570

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Fentanyl)
Number of subjects: 30
Study: 8665880

Group type: EXPERIMENTAL
Intervention: Midazolam followed by vecuronium 0.1 mg kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Midazolam followed by atracurium 0.5 mg kg‐1
Number of subjects: 30
Study: 2667526

Group type: EXPERIMENTAL
Intervention: Combination of luffa operculata D4, kalium bicromicum D4 and cinnabaris D3
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Combination of kalium bicromicum D4 and cinnabaris D3
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Luffa operculata D4
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 1002948

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavior therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate combined with behavior therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavior therapy and placebo
Number of subjects: 0
Study: 30830727

Group type: EXPERIMENTAL
Intervention: pemafibrate 0.2 mg/d
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: pemafibrate 0.4 mg/d
Number of subjects: 166

Group type: COMPARATOR
Intervention: placebo/pemafibrate 0.2 mg/d
Number of subjects: 166
Study: 28832217

Group type: EXPERIMENTAL
Intervention: Positively adjusted Pain Catastrophizing Scale (PCS)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard Pain Catastrophizing Scale (PCS)
Number of subjects: 122
Study: 25336333

Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m² daily for 5 days
Number of subjects: 149

Group type: COMPARATOR
Intervention: Decitabine 20 mg/m² daily for 5 days plus oral valproic acid 50 mg/kg daily for 7 days
Number of subjects: 149
Study: 22451457

Group type: EXPERIMENTAL
Intervention: Medical compression stockings (MCS; 15-20 mmHg)
Number of subjects: 108

Group type: COMPARATOR
Intervention: No compression treatment
Number of subjects: 108
Study: 23270247

Group type: EXPERIMENTAL
Intervention: Spanishneedles leaves group (n=48)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (n=48)
Number of subjects: 96
Study: 18450530

Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures (TC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control sutures (non-coated)
Number of subjects: 26
Study: 18219769

Group type: EXPERIMENTAL
Intervention: Technique A (stapling after full devascularization and mobilization of the gastric curve)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Technique B (stapling as soon as the lesser sac is entered)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 40
Study: 15277160

Group type: EXPERIMENTAL
Intervention: Cactus pear fruit (250 g fresh fruit pulp)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Vitamin C (75 mg twice daily)
Number of subjects: 18
Study: 11998113

Group type: EXPERIMENTAL
Intervention: Early catheter removal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard catheter removal (not specified in the abstract)
Number of subjects: 0
Study: 9062414

Group type: EXPERIMENTAL
Intervention: Thymidylate synthase (TS) immunostaining in primary colorectal tumours
Number of subjects: 134

Group type: COMPARATOR
Intervention: Normal mucosal tissue levels of TS immunostaining
Number of subjects: 134
Study: 8432822

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study: 3318445

Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe) 1,200 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ibuprofen 1,200 mg
Number of subjects: 36
Study: 30997690

Group type: EXPERIMENTAL
Intervention: Risk communication intervention
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Goal‐Setting, Planning and Self‐Monitoring (GPS) intervention
Number of subjects: 97

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 97
Study: 28985142

Group type: EXPERIMENTAL
Intervention: Sour cherries (500 g daily for 30 days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Apples (500 g daily for 30 days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 34
Study: 26120851

Group type: EXPERIMENTAL
Intervention: Interactive injection risk intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Didactic injection risk intervention
Number of subjects: 300
Study: 24854806

Group type: EXPERIMENTAL
Intervention: Physical Appearance Comparison Scale-Revised (PACS-R)
Number of subjects: 1176
Study: 22370318

Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg/d
Number of subjects: 924

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 924
Study: 20659602

Group type: EXPERIMENTAL
Intervention: Probiotic prophylaxis (1 capsule of Probaclac Vaginal containing 8 billion CFUs of Lactobacillus rhamnosus, L acidophilus, and Streptococcus thermophilus)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 120
Study: 18834368

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention (monthly 1-hour education programme)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Routine practice (control group)
Number of subjects: 160
Study: 15827569

Group type: EXPERIMENTAL
Intervention: Citalopram (7.5 mg intravenously)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11978284

Group type: EXPERIMENTAL
Intervention: Preoperative recombinant human erythropoietin therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: No erythropoietin therapy (Control)
Number of subjects: 41
Study: 10404444

Group type: EXPERIMENTAL
Intervention: Intervention group GPs received telephonic communication during admission and printed information about care and postdischarge recommendations.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group GPs received standard level of communication.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Follow-up attendance rates for intervention and control patients.
Number of subjects: 60
Study: 8626885

Group type: EXPERIMENTAL
Intervention: Nefazodone (200 mg every 12 hours) and Propranolol (40 mg every 12 hours)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nefazodone alone
Number of subjects: 18
Study: 2248389

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 64

Group type: COMPARATOR
Intervention: Regional anesthesia
Number of subjects: 64
Study: 6448025

Group type: EXPERIMENTAL
Intervention: Topical 1% clindamycin hydrochloride hydrate applied twice daily for eight weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vehicle alone applied twice daily for eight weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Topical 1% clindamycin hydrochloride hydrate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 14
Study: 30931484

Group type: EXPERIMENTAL
Intervention: 12-week rehabilitation programme with education and physical training
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 58
Study: 28261906

Group type: EXPERIMENTAL
Intervention: Two-piece implant with a progressive platform widening and a platform switching connection (SP)
Number of subjects: 47

Group type: COMPARATOR
Intervention: One-piece implant with a machined collar (TG)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (TG)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Test (SP)
Number of subjects: 47
Study: 26432067

Group type: EXPERIMENTAL
Intervention: FMISO-PET assessment during radiochemotherapy
Number of subjects: 16
Study: 23271350

Group type: EXPERIMENTAL
Intervention: TIPP technique using a soft mesh with a memory ring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lichtenstein method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TIPP technique
Number of subjects: 0
Study: 21555700

Group type: EXPERIMENTAL
Intervention: Early palliative care integrated with standard oncology care
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard oncology care alone
Number of subjects: 151
Study: 19752419

Group type: EXPERIMENTAL
Intervention: 1‐mg intravitreal triamcinolone
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: 4‐mg intravitreal triamcinolone
Number of subjects: 271

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: 1‐mg vs 4‐mg intravitreal triamcinolone
Number of subjects: 271

Group type: COMPARATOR
Intervention: Observation and 1‐mg intravitreal triamcinolone
Number of subjects: 271
Study: 17317080

Group type: EXPERIMENTAL
Intervention: Web-based decision support
Number of subjects: 463

Group type: COMPARATOR
Intervention: Printed brochure
Number of subjects: 463

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 463
Study: 15537905

Group type: EXPERIMENTAL
Intervention: 3 mg of anti-interleukin-12 per kilogram
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 11340321

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol concentrations in erythrocyte membranes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ratio of alpha-tocopherol in erythrocyte membranes to alpha-tocopherol in plasma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alpha-tocopherolquinone/alpha-tocopherol ratio in plasma and erythrocyte membranes
Number of subjects: 0
Study: 9773840

Group type: EXPERIMENTAL
Intervention: Early feeding regimen (early-continuous, early-bolus)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Antenatal steroid administration
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Feeding of human milk
Number of subjects: 132

Group type: COMPARATOR
Intervention: Continuous feeding
Number of subjects: 132
Study: 7826790

Group type: EXPERIMENTAL
Intervention: Midwife top‐up doses of 0.25% bupivacaine 10 ml
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.125% bupivacaine 10 ml h‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patient-controlled extradural analgesia (PCEA) with self‐administered 3‐ml bolus doses of 0.25% bupivacaine
Number of subjects: 30
Study: 2899977

Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Levobunolol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 30296635

Group type: EXPERIMENTAL
Intervention: UHCE approach (preventive multidimensional health assessment and coordinated care-pathways)
Number of subjects: 1844
Study: 29798443

Group type: EXPERIMENTAL
Intervention: Ginkgo Leaves Soft-gel Capsule and Qiangli Dingxuan tablets (Drug group)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation gymnastics (Group C)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (A)
Number of subjects: 93
Study: 24856939

Group type: EXPERIMENTAL
Intervention: 6-month physical activity stimulation program involving counselling through motivational interviewing, home-based physiotherapy, and 4 months of fitness training.
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 6-month physical activity stimulation program
Number of subjects: 49

Group type: COMPARATOR
Intervention: usual paediatric physiotherapy
Number of subjects: 49
Study: 22298804

Group type: EXPERIMENTAL
Intervention: Cotreatment with pegvisomant (15‐30 mg twice a week) and SA (half the usual dosage)
Number of subjects: 18

Group type: COMPARATOR
Intervention: SA monotherapy
Number of subjects: 18
Study: 20472532

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mechanical ventilation (MV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surfactant administration
Number of subjects: 0
Study: 19356426

Group type: EXPERIMENTAL
Intervention: Systematic heart rate control (oral and intravenous beta-blockade for a target heart rate ≤60 beats/min) in single-source CT
Number of subjects: 200

Group type: COMPARATOR
Intervention: No premedication in single-source CT
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Systematic heart rate control in dual-source CT
Number of subjects: 200

Group type: COMPARATOR
Intervention: No premedication in dual-source CT
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Systematic heart rate control in single-source CT
Number of subjects: 200
Study: 15161787

Group type: EXPERIMENTAL
Intervention: rosiglitazone (8 mg/day)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: metformin (1,500 mg/day)
Number of subjects: 74

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 74
Study: 11578882

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5 microg/kg/min for induction and intubation; decreased to 0.25 microg/kg/min after intubation)
Number of subjects: 2438

Group type: COMPARATOR
Intervention: Fentanyl (administered according to anesthesiologists' usual practice)
Number of subjects: 2438
Study: 9768439

Group type: EXPERIMENTAL
Intervention: Renal transplant patients
Number of subjects: 51

Group type: COMPARATOR
Intervention: Renal patients
Number of subjects: 51
Study: 7816293

Group type: EXPERIMENTAL
Intervention: Dilution of the vehicle with benzyl alcohol saline (BAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (placebo control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injection of 0.1 ml of the vehicle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injection of 0.33 ml of the vehicle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Making the vehicle iso-osmotic
Number of subjects: 0
Study: 3046812

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 30946270

Group type: EXPERIMENTAL
Intervention: Fast-eccentric training
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Fast-concentric training
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Slow-eccentric training
Number of subjects: 41

Group type: COMPARATOR
Intervention: All training groups
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: All training modalities
Number of subjects: 41
Study: 30119986

Group type: EXPERIMENTAL
Intervention: Cephalosporins
Number of subjects: 98

Group type: COMPARATOR
Intervention: Fluoroquinolone and trimethoprim-sulfamethoxazole
Number of subjects: 98

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 98

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 98

Group type: COMPARATOR
Intervention: Cephalexin
Number of subjects: 98

Group type: COMPARATOR
Intervention: Cefdinir
Number of subjects: 98